X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4495) 4495
Newspaper Article (630) 630
Publication (285) 285
Newsletter (135) 135
Book Review (64) 64
Magazine Article (63) 63
Trade Publication Article (31) 31
Book Chapter (25) 25
Book / eBook (21) 21
Transcript (4) 4
Web Resource (3) 3
Conference Proceeding (2) 2
Dissertation (2) 2
Streaming Video (2) 2
Data Set (1) 1
Paper (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3716) 3716
angioplasty (2515) 2515
male (1903) 1903
female (1839) 1839
index medicus (1627) 1627
middle aged (1596) 1596
cardiac & cardiovascular systems (1534) 1534
aged (1499) 1499
treatment outcome (1213) 1213
stents (1107) 1107
transluminal angioplasty (891) 891
mortality (831) 831
cost-benefit analysis (807) 807
surgery (727) 727
heart attacks (720) 720
cardiology (719) 719
angioplasty, balloon, coronary - economics (711) 711
risk factors (696) 696
cardiovascular disease (624) 624
time factors (597) 597
care and treatment (564) 564
percutaneous coronary intervention (556) 556
adult (531) 531
cardiac patients (529) 529
angioplasty, balloon, coronary (527) 527
myocardial infarction - therapy (521) 521
peripheral vascular disease (486) 486
aged, 80 and over (483) 483
coronary heart disease (482) 482
patients (482) 482
coronary vessels (481) 481
stent (481) 481
retrospective studies (476) 476
coronary artery bypass (472) 472
coronary disease - therapy (462) 462
hospitals (460) 460
analysis (433) 433
follow-up studies (433) 433
united states (420) 420
outcomes (415) 415
prospective studies (410) 410
medicine, general & internal (402) 402
acute myocardial-infarction (394) 394
research (375) 375
revascularization (367) 367
stents - economics (362) 362
disease (354) 354
studies (354) 354
balloon angioplasty (344) 344
intervention (343) 343
myocardial infarction (338) 338
heart attack (337) 337
cardiovascular (324) 324
management (315) 315
abridged index medicus (311) 311
risk assessment (306) 306
health care costs (304) 304
coronary angiography (300) 300
trial (298) 298
platelet aggregation inhibitors - therapeutic use (296) 296
restenosis (295) 295
health aspects (293) 293
angioplasty, balloon, coronary - adverse effects (291) 291
medical research (290) 290
clinical trials (285) 285
coronary artery disease (279) 279
angioplasty, balloon, coronary - methods (278) 278
angiography (274) 274
coronary artery bypass - economics (274) 274
medicine & public health (274) 274
quality of life (271) 271
therapy (271) 271
coronary artery disease - therapy (268) 268
randomized controlled trials as topic (264) 264
costs and cost analysis (260) 260
medicine (259) 259
drug-eluting stents (254) 254
ischemia (252) 252
myocardial infarction - mortality (250) 250
cost-effectiveness (246) 246
acute coronary syndromes (245) 245
diabetes (240) 240
hospital costs (236) 236
usage (234) 234
follow-up (233) 233
heart (233) 233
cardiovascular diseases (229) 229
angina pectoris (227) 227
myocardial-infarction (224) 224
patient outcomes (219) 219
coronary disease - economics (216) 216
risk (215) 215
medicine, experimental (214) 214
stroke (213) 213
cardiology and cardiovascular medicine (212) 212
recurrence (212) 212
thrombosis (210) 210
stenosis (207) 207
myocardial infarction - economics (205) 205
patient selection (200) 200
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5165) 5165
German (94) 94
French (35) 35
Italian (21) 21
Japanese (21) 21
Spanish (19) 19
Portuguese (18) 18
Russian (10) 10
Polish (6) 6
Dutch (5) 5
Swedish (5) 5
Hungarian (4) 4
Czech (3) 3
Chinese (2) 2
Danish (2) 2
Finnish (2) 2
Hebrew (2) 2
Norwegian (2) 2
Slovak (2) 2
Croatian (1) 1
Serbian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Catheterization and Cardiovascular Interventions, ISSN 1522-1946, 10/2014, Volume 84, Issue 4, pp. 546 - 554
Objectives To study the economic impact on payers and providers of the four main endovascular strategies for the treatment of infrainguinal peripheral artery... 
stent | balloon | drug coated/eluting | peripheral arterial disease | economics/cost‐effectiveness | balloon angioplasty | endovascular intervention | drug eluting | economics/cost-effectiveness | CARDIAC & CARDIOVASCULAR SYSTEMS | PACLITAXEL-ELUTING STENTS | POPLITEAL ARTERIES | RESILIENT RANDOMIZED-TRIAL | FOLLOW-UP | NITINOL STENT IMPLANTATION | PILOT TRIAL | LESIONS | SUPERFICIAL FEMORAL-ARTERY | RESTENOSIS | Drug Costs | Insurance, Health, Reimbursement | Markov Chains | Stents - economics | Constriction, Pathologic | Popliteal Artery | United States | Coated Materials, Biocompatible - economics | Humans | Medicare - economics | Models, Economic | Angioplasty, Balloon - adverse effects | Cost Savings | Vascular Access Devices - economics | Femoral Artery | Budgets | Cardiovascular Agents - economics | Cardiovascular Agents - administration & dosage | Decision Support Techniques | Metals - economics | Drug-Eluting Stents - economics | Treatment Outcome | Peripheral Arterial Disease - economics | Angioplasty, Balloon - instrumentation | Outcome and Process Assessment (Health Care) - economics | Peripheral Arterial Disease - therapy | Health Care Costs | Peripheral Arterial Disease - diagnosis | Cost-Benefit Analysis | Angioplasty, Balloon - economics | Germany | Transluminal angioplasty | Markov processes | Budget | Models | Analysis
Journal Article
Journal Article
Annals of Vascular Surgery, ISSN 0890-5096, 2016, Volume 36, pp. 7 - 12
Journal Article
Journal of Vascular Surgery, ISSN 0741-5214, 2011, Volume 54, Issue 4, pp. 1021 - 1031.e1
Purpose Debate exists as to the benefit of angioplasty vs bypass graft in the treatment of lower extremity peripheral vascular disease. The associated costs... 
Surgery | SURGERY | INTERVENTIONS | LOWER-EXTREMITY | MANAGEMENT | ENDOVASCULAR REVASCULARIZATION | CONSENSUS | INTERMITTENT CLAUDICATION | RANDOMIZED-TRIAL | PERIPHERAL VASCULAR DISEASE | COMPLICATIONS | PERIPHERAL ARTERIAL-DISEASE | LEG BASIL | Amputation - trends | United States - epidemiology | Length of Stay - economics | Humans | Male | Ischemia - mortality | Angioplasty, Balloon - adverse effects | Vascular Surgical Procedures - trends | Ischemia - economics | Patient Selection | Quality Indicators, Health Care - economics | Health Care Costs - trends | Amputation - economics | Intermittent Claudication - economics | Time Factors | Vascular Surgical Procedures - mortality | Female | Intermittent Claudication - mortality | Intermittent Claudication - therapy | Odds Ratio | Angioplasty, Balloon - trends | Limb Salvage - trends | Stents | Vascular Surgical Procedures - economics | Limb Salvage - economics | Reoperation | Hospital Mortality | Intermittent Claudication - surgery | Risk Assessment | Comorbidity | Risk Factors | Ischemia - therapy | Logistic Models | Treatment Outcome | Chi-Square Distribution | Angioplasty, Balloon - instrumentation | Databases as Topic | Outcome and Process Assessment (Health Care) - economics | Angioplasty, Balloon - mortality | Vascular Surgical Procedures - adverse effects | Angioplasty, Balloon - economics | Length of Stay - trends | Ischemia - surgery | Aged | Outcome and Process Assessment (Health Care) - trends | Quality Indicators, Health Care - trends | Lower Extremity - blood supply | Ischemia | Coronary artery bypass | Angioplasty
Journal Article
The European Journal of Health Economics, ISSN 1618-7598, 3/2016, Volume 17, Issue 2, pp. 185 - 193
Aims To examine the cost-effectiveness of intravascular ultrasound (IVUS) use during percutaneous coronary intervention (PCI) with drug-eluting stents (DES) in... 
Health care costs | Health outcomes | Angiography | Utilities costs | Ultrasonography | Implicit costs | Percutaneous transluminal coronary angioplasty | Diabetes | Stents | Cost efficiency | Health Economics | Economic Policy | Public Health | Drug-eluting stent | Percutaneous coronary intervention | Health Care Management | Intravascular ultrasound | Cost-effectiveness analyses | Pharmacoeconomics and Health Outcomes | Medicine & Public Health | Economic evaluations | Public Finance & Economics | PACLITAXEL | DIABETES-MELLITUS | ELUTING STENTS | STENT IMPLANTATION | COST | HEALTH POLICY & SERVICES | ECONOMICS | CLINICAL-OUTCOMES | Quality-Adjusted Life Years | Markov Chains | Coronary Disease - economics | Humans | Middle Aged | Drug-Eluting Stents - economics | Percutaneous Coronary Intervention - methods | Cost-Benefit Analysis | Health Care Costs - statistics & numerical data | Italy | Percutaneous Coronary Intervention - economics | Coronary Disease - surgery | Ultrasonography, Interventional - economics | Transluminal angioplasty | Diabetics | Chronic kidney failure | Cardiac patients | Economic aspects | Markov processes | Medical care | Cost benefit analysis | Coronary heart disease | Medical care, Cost of | Quality management | Studies | Economic models | Health economics | Health care expenditures | Medical imaging | Economic theory | Cardiovascular disease | Economic impact | Cost analysis | Acute coronary syndromes | Economic statistics
Journal Article
Cardiovascular Drugs and Therapy, ISSN 0920-3206, 2/2017, Volume 31, Issue 1, pp. 39 - 49
This study aimed to examine the cost-effectiveness of CYP2C19 loss-of-function and gain-of-function allele guided (LOF/GOF-guided) antiplatelet therapy in... 
Prasugrel | Medicine & Public Health | CYP2C19 genotype | Clopidogrel | Cardiology | Ticagrelor | Acute coronary syndrome | Cost-effectiveness | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | ORAL ANTIPLATELET | GENOTYPE | GUIDELINES | PHARMACOLOGY & PHARMACY | TREATMENT PLATELET REACTIVITY | ELEVATION MYOCARDIAL-INFARCTION | ARTERY-DISEASE | Predictive Value of Tests | Acute Coronary Syndrome - economics | Humans | Models, Economic | Pharmacogenomic Testing - economics | Purinergic P2Y Receptor Antagonists - metabolism | Purinergic P2Y Receptor Antagonists - adverse effects | Time Factors | Ticlopidine - economics | Acute Coronary Syndrome - enzymology | Myocardial Infarction - etiology | Platelet Aggregation Inhibitors - adverse effects | Quality-Adjusted Life Years | Prasugrel Hydrochloride - economics | Risk Factors | Genotype | Ticlopidine - analogs & derivatives | Phenotype | Stroke - etiology | Adenosine - analogs & derivatives | Acute Coronary Syndrome - therapy | Adenosine - economics | Coronary Thrombosis - etiology | Percutaneous Coronary Intervention - economics | Hemorrhage - chemically induced | Monte Carlo Method | Drug Costs | Platelet Aggregation Inhibitors - economics | Ticlopidine - therapeutic use | United States | Hemorrhage - economics | Patient Selection | Adenosine - therapeutic use | Computer Simulation | Pharmacogenomic Variants | Myocardial Infarction - economics | Platelet Aggregation Inhibitors - metabolism | Platelet Aggregation Inhibitors - therapeutic use | Coronary Thrombosis - economics | Purinergic P2Y Receptor Antagonists - therapeutic use | Purinergic P2Y Receptor Antagonists - economics | Decision Support Techniques | Stroke - economics | Cytochrome P-450 CYP2C19 - genetics | Treatment Outcome | Prasugrel Hydrochloride - therapeutic use | Cost-Benefit Analysis | Cytochrome P-450 CYP2C19 - metabolism | Acute Coronary Syndrome - genetics | Transluminal angioplasty | Monte Carlo method | Analysis | Cardiac patients | Cytochrome P-450 | Health care industry | Cost benefit analysis | Coronary heart disease | Medical care, Cost of
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2015, Volume 65, Issue 9, pp. 920 - 927
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 01/2013, Volume 11, Issue 1, pp. 81 - 91
Background:  The CYP2C19 genotype is a predictor of adverse cardiovascular events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary... 
clopidogrel | cost‐effectiveness | prasugrel | antiplatelet therapy | genetic testing | acute coronary syndromes | Antiplatelet therapy | Prasugrel | Clopidogrel | Genetic testing | Acute coronary syndromes | Cost-effectiveness | cost-effectiveness | LAST YEAR | CYP2C19 GENOTYPE | TREATED PATIENTS | BYPASS GRAFT-SURGERY | ATRIAL-FIBRILLATION | ACUTE MYOCARDIAL-INFARCTION | PERIPHERAL VASCULAR DISEASE | ST-SEGMENT ELEVATION | HEMATOLOGY | OF-CARE | CLINICAL-OUTCOMES | Prasugrel Hydrochloride | Predictive Value of Tests | Thiophenes - therapeutic use | Percutaneous Coronary Intervention - mortality | Acute Coronary Syndrome - economics | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Thiophenes - metabolism | Medicare - economics | Models, Economic | Pharmacogenetics - economics | Time Factors | Ticlopidine - economics | Myocardial Infarction - etiology | Insurance, Health, Reimbursement - economics | Quality-Adjusted Life Years | Genetic Predisposition to Disease | Risk Assessment | Gene Frequency | Risk Factors | Piperazines - therapeutic use | Ticlopidine - analogs & derivatives | Phenotype | Acute Coronary Syndrome - therapy | Thrombosis - genetics | Percutaneous Coronary Intervention - economics | Percutaneous Coronary Intervention - adverse effects | Thrombosis - economics | Drug Costs | Platelet Aggregation Inhibitors - economics | Markov Chains | Ticlopidine - therapeutic use | United States | Acute Coronary Syndrome - mortality | Piperazines - economics | Piperazines - metabolism | Computer Simulation | Hemorrhage - etiology | Ticlopidine - metabolism | Thiophenes - economics | Platelet Aggregation Inhibitors - metabolism | Thrombosis - prevention & control | Platelet Aggregation Inhibitors - therapeutic use | Decision Support Techniques | Kaplan-Meier Estimate | Treatment Outcome | Cerebrovascular Disorders - etiology | Aryl Hydrocarbon Hydroxylases - metabolism | Disease-Free Survival | Health Care Costs | Cytochrome P-450 CYP2C19 | Cost-Benefit Analysis | Acute Coronary Syndrome - diagnosis | Acute Coronary Syndrome - genetics | Genetic Testing - economics | Transluminal angioplasty | Care and treatment | Medicare | Analysis | Cardiac patients | Cytochrome P-450 | Markov processes | Cost benefit analysis | Coronary heart disease | Genetic screening | Angina pectoris | Genotype & phenotype
Journal Article
BMC Cardiovascular Disorders, ISSN 1471-2261, 01/2016, Volume 16, Issue 1, p. 13
Background: Annual direct costs for cardiovascular (CV) diseases in the United States are approximately $195.6 billion, with many high-risk patients remaining... 
Cardiovascular events | Clinical burden | Economic burden | Hyperlipidemia | HEART-DISEASE | CARDIAC & CARDIOVASCULAR SYSTEMS | CHRONIC DISEASE | COSTS | SCORE | CHOLESTEROL | RISK | Multivariate Analysis | United States - epidemiology | Myocardial Infarction - epidemiology | Length of Stay - economics | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Case-Control Studies | Hyperlipidemias - epidemiology | Young Adult | Coronary Artery Bypass - statistics & numerical data | Adult | Female | Myocardial Infarction - economics | Myocardial Revascularization - economics | Myocardial Revascularization - statistics & numerical data | Stroke - epidemiology | Retrospective Studies | Heart Failure - economics | Heart Failure - epidemiology | Length of Stay - statistics & numerical data | Databases, Factual | Angina, Unstable - economics | Angina, Unstable - epidemiology | Stroke - economics | Hyperlipidemias - economics | Coronary Artery Bypass - economics | Ischemic Attack, Transient - economics | Ischemic Attack, Transient - epidemiology | Propensity Score | Health Care Costs | Adolescent | Percutaneous Coronary Intervention - statistics & numerical data | Aged | Percutaneous Coronary Intervention - economics | Cohort Studies | Hospitalization - economics | Transluminal angioplasty | Complications and side effects | Care and treatment | Unstable angina | Development and progression | Research | Health aspects | Heart attack | Risk factors
Journal Article
Circulation, ISSN 0009-7322, 02/2013, Volume 127, Issue 7, pp. 820 - 831
Background-Studies from the balloon angioplasty and bare metal stent eras have demonstrated that coronary artery bypass grafting (CABG) is cost-effective... 
percutaneous coronary intervention | diabetes mellitus | drug-eluting stents | cost-benefit analysis | coronary artery bypass grafting | REVASCULARIZATION | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | EFFICACY | MEDICAL COSTS | ARTS | ANGIOPLASTY | RANDOMIZATION | PERIPHERAL VASCULAR DISEASE | QUALITY-OF-LIFE | OUTCOMES | STANDARD | Diabetic Angiopathies - surgery | Ambulatory Care - utilization | Coronary Artery Disease - surgery | Follow-Up Studies | Humans | Middle Aged | Diabetes Mellitus, Type 2 - economics | Male | Coronary Artery Bypass - mortality | Angioplasty, Balloon, Coronary - mortality | Drug-Eluting Stents - statistics & numerical data | Female | Quality-Adjusted Life Years | Hospital Costs - statistics & numerical data | Diabetic Angiopathies - economics | Coronary Artery Disease - economics | Diabetic Angiopathies - mortality | Drug-Eluting Stents - economics | Angioplasty, Balloon, Coronary - economics | Coronary Artery Disease - mortality | Coronary Artery Bypass - economics | Diabetes Mellitus, Type 1 - mortality | Diabetic Angiopathies - therapy | Coronary Artery Disease - therapy | Diabetes Mellitus, Type 1 - economics | Cost-Benefit Analysis | Diabetes Mellitus, Type 2 - mortality | Quality of Life | Aged | Ambulatory Care - economics | Care and treatment | Usage | Coronary artery bypass | Angioplasty | Patient outcomes | Drug-eluting stents | Diabetes | Coronary heart disease | Health aspects
Journal Article
Circulation, ISSN 0009-7322, 01/2010, Volume 121, Issue 1, pp. 71 - 79
Background-In patients with acute coronary syndromes and planned percutaneous coronary intervention, the Trial to Assess Improvement in Therapeutic Outcomes by... 
Infarction | Coronary disease | Thrombus | Cost- benefit analysis | Revascularization | coronary disease | revascularization | IMPACT | CARDIAC & CARDIOVASCULAR SYSTEMS | CARDIOVASCULAR EVENTS | cost-benefit analysis | infarction | PERIPHERAL VASCULAR DISEASE | thrombus | CLINICAL-OUTCOMES | Platelet Aggregation Inhibitors - economics | Prasugrel Hydrochloride | Thiophenes - therapeutic use | United States - epidemiology | Myocardial Infarction - mortality | Follow-Up Studies | Ticlopidine - therapeutic use | Acute Coronary Syndrome - economics | Humans | Acute Coronary Syndrome - mortality | Hemorrhage - mortality | Piperazines - economics | Angioplasty, Balloon, Coronary | Drug Costs - statistics & numerical data | Life Expectancy | Ticlopidine - economics | Myocardial Infarction - economics | Thiophenes - economics | Stroke - mortality | Platelet Aggregation Inhibitors - therapeutic use | Databases, Factual | Multicenter Studies as Topic - statistics & numerical data | Randomized Controlled Trials as Topic - statistics & numerical data | Thrombolytic Therapy - economics | Combined Modality Therapy | Piperazines - therapeutic use | Ticlopidine - analogs & derivatives | Acute Coronary Syndrome - drug therapy | Outcome and Process Assessment (Health Care) - economics | Myocardial Infarction - drug therapy | Cost-Benefit Analysis | Hospitalization - economics | Usage | Patient outcomes | Clopidogrel | Drug therapy | Comparative analysis | Health aspects | Heart attack
Journal Article
Annals of Vascular Surgery, ISSN 0890-5096, 2016, Volume 31, pp. 111 - 123
Journal Article
Catheterization and Cardiovascular Interventions, ISSN 1522-1946, 12/2016, Volume 88, Issue 7, pp. 1017 - 1024
Journal Article